Monrol Signing Agreement to License its GMP Grade Lu-177 n.c.a Production Technology to Curium
28.1.2022 15:47:00 EET | Business Wire | Press release
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced it has signed an agreement with Curium Netherlands B.V (Curium) to license its GMP grade medical radioisotope, no-carrier-added 177Lu (n.c.a. 177Lu) cutting-edge production technology LuMagic®. This agreement will enable transfer of relevant equipment and supply from Monrol to Curium.
Monrol is one of the few producers of Lutetium-177 n.c.a worldwide, having uninterrupted worldwide supply capabilities. Monrol Lu-177 n.c.a production process is an exclusive processing technology having cleaner and safer production method with stable isotope enrichment capability. Curium planning to manufacture the product Lu-177 n.c.a in its Petten production facility, Netherlands. This licence is offering significant opportunities both for Curium; one of the world’s largest nuclear medicine companies and Monrol; a company which develops, manufactures, and distributes world-class radiopharmaceutical products, radioisotopes to improve quality of life of cancer patients globally.
Lutetium-177 n.c.a is a radioisotope of choice for targeted radionuclide therapy. Lu-177 n.c.a production process enables treatment options that have the potential to improve treatment outcomes for certain cancer patients today and more potential treatment options in future under clinical development. Unique properties of Lutetium-177 n.c.a makes it a theranostically desirable radioisotope for peptide receptor radionuclide therapy (PRRT) to treat certain cancers like Neuro Endocrine Tumors (NET) and Prostate cancer.
In line with our mission to improve the quality of life of cancer patients globally, Monrol is establishing strategic partnerships with multinational pharmaceutical companies and constructing a new production facility compliant with FDA 21 CFR Part 211 quality standards which will have an annual production capacity of 60 thousand doses. With its location close to Istanbul's transportation hub, the new facility will benefit from a worldwide logistics network and agreements with cargo services to 320 destinations worldwide.
"Lu-177 n.c.a contributes to our mission to improve quality of life of cancer patients globally. Our new GMP certified facility exclusively designed for theranostic R&D and production with cutting edge technology will enable us to maximize supply of high-quality Lutetium. We are committed to working closely with Curium to potentially bring new therapeutic radiopharmaceutical agents into market soon to improve patients’ lives having life threatening diseases” said Monrol General Manager Aydın Kucuk”.
John Sylvester CEO of Curium’s SPECT and International businesses commented “We are delighted with Monrol as a technology partner, after extensive benchmarking this technology gave both the highest quality product with the most efficient process, as it is already proven and ‘plug and play’ in nature the time to market will be very short”.
About Monrol
Monrol is one of the world’s largest nuclear medicine companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in Istanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today’s nimble, lean, virtual companies effectively taking new product concepts into clinical trials and demonstrating proof of concept and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 50 countries around the globe. To learn more, visit www.monrol.com
About Curium
Curium is the world’s largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220128005174/en/
Contact information
Eczacıbaşı Monrol
Mr. Aydın Küçük
General Manager
Email: aydin.kucuk@monrol.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer8.10.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL), each approved for use in combination with the other for the treatment of adult patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases who have previously received available standard therapies. These are the first marketing authorizations for either medicine anywhere in the world. The approvals are expected to benefit patients in Armenia as well as patients who travel to Armenia for treatment under the care of Armenian oncologists. Botensilimab is a multifunctional, Fc-enhanced anti-CTLA-4 antibody designed to activate innate and adaptive antitumor immune responses, including in tumors that have historically responded poorly to conventional immunotherapy. Balstilimab is an anti-PD-1 antibody de
NTT DOCOMO BUSINESS and Classiq Enter Strategic Business Partnership to Accelerate Enterprise Adoption of Quantum Computing8.10.2026 14:00:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) and Classiq Technologies G.K., the Japanese subsidiary of Classiq Technologies Ltd., today announced a memorandum of understanding establishing a strategic business partnership aimed at accelerating enterprise adoption of quantum computing1 in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007985427/en/ NTT DOCOMO BUSINESS and Classiq logos Under the partnership, NTT DOCOMO BUSINESS will propose and sell the Classiq quantum software development platform and work with Classiq to help enterprises identify, develop and validate quantum computing use cases. Classiq will provide the platform, along with expertise and technical support related to quantum algorithms and quantum software technologies. The two companies will combine Classiq’s quantum software technology with NTT DOCOMO BUSINESS’s experience bringing advanced technologies into real-world ent
NIQ Reaches Key Milestone in Acquisition of The U Group, Strengthening Trusted Intelligence and The Full View™8.10.2026 13:45:00 EEST | Press release
NielsenIQ (NYSE: NIQ) today announced that its wholly-owned Australian subsidiary, Nielsen Connect Australia Pty Ltd (NIQ Australia), has exceeded the 90% shareholder acceptance threshold under its off-market takeover bid for The U Group & Co Limited (The U Group), an Australian-based company specializing in consumer participation, receipt intelligence, and AI-powered data processing capabilities. Achieving the acceptance threshold represents a significant milestone in the transaction process and enables NIQ Australia to proceed with the compulsory acquisition of the remaining shares in The U Group in accordance with applicable Australian law. Building on a successful five-year partnership, the transaction strengthens NIQ's trusted intelligence foundation and advances its strategy to deliver the industry's most complete understanding of consumer buying behavior. By bringing together NIQ's measurement, analytics, and consumer intelligence capabilities with The U Group's consumer partici
Movado Group, Inc. Enters Into Agreement to Sell Majority Interest in EBEL8.10.2026 13:45:00 EEST | Press release
Movado Group, Inc. (NYSE: MOV) today announced that it has entered into a binding agreement to sell a 95% interest in its EBEL brand for $66.5 million to a strategic buyer group led by Montres Journe SA (“Montres Journe”), a Geneva-based luxury watch manufacturer, with the participation of Chanel (“Chanel”), the luxury house, and Pierre Jacques, a renowned figure in the Swiss watch industry, who will serve as Chief Executive Officer of EBEL. The transaction is subject to customary adjustments and closing conditions with Movado Group retaining a 5% interest in the business. Founded in Switzerland in 1911, EBEL is a premium luxury watch brand known for its distinctive design, craftsmanship and rich heritage. This strategic sale allows Movado Group to sharpen its focus on its core accessible luxury and fashion watch and jewelry portfolio, while providing EBEL with a new ownership platform specifically positioned to support the brand’s long-term development. With the expertise and capital
Network X 2026 Brings Europe’s Telecom Leaders Together in Vienna to Define the Future of Connectivity8.10.2026 13:42:00 EEST | Press release
Network X 2026 unites the telecommunications industry’s most influential executives and technology leaders at VIECON Vienna from 13-15 October, with a high-powered Headliners programme focused on the forces reshaping the future of connectivity. Across three days, CEOs, CTOs, technology chiefs, regulators and industry experts from leading operators and technology organisations will examine how artificial intelligence, network sovereignty, broadband networks, 6G, cloud, infrastructure investment and new business models are changing the role of the telecom operator. The programme features senior executives from A1 Group, Swisscom, Drei Austria, A1 Austria, Orange, Deutsche Telekom, Vodafone Group, Kyivstar, 4iG Telecommunications Holding, Yettel Bulgaria, Play Poland, Orange Slovensko, NGMN Alliance and other major players across the global connectivity ecosystem. Industry Leaders Take the Stage Network X 2026 will feature a series of keynote presentations, fireside conversations and high
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom